<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673920</url>
  </required_header>
  <id_info>
    <org_study_id>ACT4394g</org_study_id>
    <secondary_id>WA20496</secondary_id>
    <nct_id>NCT00673920</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy</brief_title>
  <acronym>FEATURE</acronym>
  <official_title>A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in
      patients with active rheumatoid arthritis who have an inadequate response to methotrexate
      therapy. Patients will be randomized 2:2:1 to receive 1) infusions of ocrelizumab 200mg iv on
      Days 1 and 15, 2) infusions of ocrelizumab 400mg iv on Day 1 and placebo iv on Day 15, or 3)
      infusions of placebo iv on Days 1 and 15. At the end of the placebo-controlled treatment
      period at 24 weeks, patients in groups 1 and 3 will be re-randomized to receive either a
      single infusion of 400mg iv ocrelizumab or 2 infusions of 200mg iv ocrelizumab, and group 2
      will receive a second single infusion of 400mg iv ocrelizumab. All patients will receive a
      stable dose of concomitant methotrexate (7.5-25mg/week) throughout the study. The anticipated
      time on study treatment is 1-2 years. Target number of patients to be enrolled in this trial
      is 300.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on analysis of results and consideration of available treatments, the overall benefit to
    risk profile of ocrelizumab was not favorable in RA.
  </why_stopped>
  <start_date type="Actual">April 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with ACR20 response</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR50, ACR70, DAS28, Eular response rate, SF-36, FACIT-Fatigue score, comparison of AE rates after single and dual infusions of ocrelizumab</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs and lab parameters; PK and PD parameters after single and dual infusions of ocrelizumab</measure>
    <time_frame>Length of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">314</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Oral or parenteral repeating dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ocrelizumab</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Adult patients, â‰¥ 18 years of age

          -  Active rheumatoid arthritis

          -  Inadequate treatment with any DMARD other than methotrexate

        Exclusion criteria:

          -  Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid
             arthritis

          -  Concurrent treatment with any DMARD other than methotrexate

          -  Previous treatment with any cell-depleting therapies

          -  Any surgical procedure in past 12 weeks, or planned within 48 weeks after baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Dummer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <disposition_first_submitted>June 28, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>June 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 4, 2013</disposition_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

